IL-1 plays an important role in the bone metabolism under physiological conditions

International Immunology

Volumn 22, Issue 10, 2010, Pages 805-816

  Lee, Young Mi ^a,c   Fujikado, Noriyuki ^a,d   Manaka, Hiroko ^a   Yasuda, Hisataka ^a,e   Iwakura, Yoichiro ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c Ewha Womans University   (South Korea)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Oriental Yeast Co Ltd   (Japan)

Author keywords

Bone resorption; Cytokine; Inflammation; Osteoblasts; Osteoclasts

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PROTEIN C FOS; PROTEIN C JUN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; BONE MARROW CELL; BONE MASS; BONE METABOLISM; CELL DIFFERENTIATION; COCULTURE; CONTROLLED STUDY; CORTICAL BONE; FEMUR; HEMATOPOIESIS; KNOCKOUT MOUSE; MACROPHAGE; MALE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THICKNESS; TRABECULAR BONE; WILD TYPE;

ANIMALS; BONE AND BONES; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMUR; GENE EXPRESSION REGULATION; INTERLEUKIN-1; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 77957336870     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxq431     Document Type: Article

References (59)

1. Suda, T., Takahashi, N. and Martin, T. J. 1992. Modulation of osteoclast differentiation. Endocr. Rev. 13:66.
2. Roodman, G. D. 1996. Advances in bone biology: the osteoclast. Endocr. Rev. 17:308.
3. Teitelbaum, S. L. 2000. Bone resorption by osteoclasts. Science 289:1504.
4. Tsuda, E., Goto, M., Mochizuki, S. et al. 1997. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234:137.
5. Yasuda, H., Shima, N., Nakagawa, N. et al. 1998. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329.
6. Yasuda, H., Shima, N., Nakagawa, N. et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95:3597.
7. Simonet, W. S., Lacey, D. L., Dunstan, C. R. et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309.
8. Lacey, D. L., Timms, E., Tan, H.-L. et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165.
9. Wong, B. R., Rho, J., Arron, J. et al. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272:25190.
10. Anderson, D. A., Maraskovsky, E., Billingsley, W. L. et al. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic function. Nature 390:175.
11. Nakagawa, N., Kinosaki, M., Yamaguchi, K. et al. 1998. RANK is the signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253:395.
12. Hsu, H., Lacey, D. L., Dunstan, C. R. et al. 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 96:3540.
13. Yasuda, H., Shima, N., Nakagawa, N. et al. 1999. A novel molecular mechanism modulating osteoclast differentiation and function. Bone 25:109.
14. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T. and Martin, T. J. 1999. Modulation of osteoclast differentiation and function by the new members of the tumour necrosis factor receptor and ligand families. Endocr. Rev. 20:345.
15. Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095.
16. Dinarello, C. A. 1997. Interleukin-1. Cytokine Growth Factor Rev. 8:253.
17. Nakae, S., Horai, R., Komiyama, Y. et al. 2003. The Role of IL-1 in the Immune System. Humana Press, Totowa, NJ.
18. Stashenko, P., Dewhirst, F. E., Rooney, M. L., Desjardins, L. A. and Heeley, J. D. 1987. Interleukin-1 beta is a potent inhibitor of bone formation in vitro. J. Bone Miner. Res. 2:559.
19. Gowen,M.,Wood,D.D., Ihrie, E. J.,McGuire,M.K. andRussell, R. G. 1983. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306:378.
20. Lorenzo, J. A., Sousa, S. L., Alander, C., Raisz, L. G. and Dinarello, C. A. 1987. Comparison of the bone-resorbing activity in the supernatants from phytohemagglutinin-stimulated human peripheral blood mononuclear cells with that of cytokines through the use of an antiserum to interleukin 1. Endocrinology 121:1164.
21. Dewhirst, F. E., Stashenko, P. P.,Mole, J. E. and Tsurumachi, T. 1985. Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. J. Immunol. 135:2562.
22. Akatsu, T., Takahashi, N., Udagawa, N. et al. 1991. Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro. J. Bone Miner. Res. 6:183.
23. Hofbauer, L. C., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L. and Khosla, S. 1999. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25:255.
24. Morony, S., Capparelli, C., Lee, R. et al. 1999. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J. Bone Miner. Res. 14:1478.
25. Jimi, E., Nakamura, I., Duong, L. T. et al. 1999. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247:84.
26. Thomson, B. M., Saklatvala, J. and Chambers, T. J. 1986. Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts. J. Exp. Med. 164:104.
27. Jimi, E., Shuto, T. and Koga, T. 1995. Macrophage colonystimulating factor and interleukin-1 alpha maintain the survival of osteoclast-like cells. Endocrinology 136:808.
28. Jimi, E., Nakamura, I., Ikebe, T., Akiyama, S., Takahashi, N. and Suda, T. 1998. Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1. J. Biol. Chem. 273:8799.
29. Miyazaki, T., Katagiri, H., Kanegae, Y. et al. 2000. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J. Cell Biol. 148:333.
30. Arend, W. P. and Dayer, J. M. 1995. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 38:151.
31. Pacifici, R. 1996. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. 11:1043.
32. Iwakura, Y. 2002. Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev. 13:341.
33. Iwakura, Y., Tosu, M., Yoshida, E. et al. 1991. Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science 253:1026.
34. Saijo, S., Asano, M., Horai, R., Yamamoto, H. and Iwakura, Y. 2002. Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum. 46:533.
35. Horai, R., Saijo, S., Tanioka, H. et al. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191:313.
36. Feige, U., Karbowski, A., Rordorf-Adam, C. and Pataki, A. 1989. Arthritis induced by continuous infusion of hr-interleukin-1 alpha into the rabbit knee-joint. Int. J. Tissue React. 11:225.
37. Joosten, L. A., Helsen, M. M., van de Loo, F. A. and van den Berg, W. B. 1996. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 39:797.
38. Ji, H., Pettit, A., Ohmura, K. et al. 2002. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J. Exp. Med. 196:77.
39. Kitazawa, R., Kimble, R. B., Vannice, J. L., Kung, V. T. and Pacifici, R. 1994. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 94:2397.
40. Kimble, R. B., Vannice, J. L., Bloedow, D. C. et al. 1994. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J. Clin. Invest. 93:1959.
41. Lorenzo, J. A., Naprta, A., Rao, Y. et al. 1998. Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 139:3022.
42. Langdahl, B. L., Lokke, E., Carstens, M., Stenkjaer, L. L. and Eriksen, E. F. 2000. Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1-receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene. J. Bone Miner. Res. 15:402.
43. Bajnok, E., Takacs, I., Vargha, P., Speer, G., Nagy, Z. and Lakatos, P. 2000. Lack of association between interleukin-1 receptor antagonist protein gene polymorphism and bone mineral density in Hungarian postmenopausal women. Bone 27:559.
44. Pacifici, R. 1992. Is there a causal role for IL-1 in postmenopausal bone loss? Calcif. Tissue Int. 50:295.
45. Pacifici, R., Vannice, J. L., Rifas, L. and Kimble, R. B. 1993. Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy. J. Clin. Endocrinol. Metab. 77:1135.
46. Khosla, S., Peterson, J. M., Egan, K., Jones, J. D. and Riggs, B. L. 1994. Circulating cytokine levels in osteoporotic and normal women. J. Clin. Endocrinol. Metab. 79:707.
47. Vargas, S. J., Naprta, A., Glaccum, M., Lee, S. K., Kalinowski, J. and Lorenzo, J. A. 1996. Interleukin-6 expression and histomorphometry of bones from mice deficient in receptors for interleukin-1 or tumor necrosis factor. J. Bone Miner. Res. 11:1736.
48. Horai, R., Asano, M., Sudo, K. et al. 1998. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187:1463.
49. Takahashi, N., Akatsu, T., Udagawa, N. et al. 1988. Osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600.
50. Kobayashi, K., Takahashi, N., Jimi, E. et al. 2000. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191:275.
51. Fujikado, N., Saijo, S., Yonezawa, T. et al. 2008. Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells. Nat. Med. 14:176.
52. Lange, J., Sapozhnikova, A., Lu, C. et al. 2010. Action of IL-1beta during fracture healing. J. Orthop. Res. 28:778.
53. Glantschnig, H., Fisher, J. E., Wesolowski, G., Rodan, G. A. and Reszka, A. A. 2003. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 10:1165.
54. Jimi, E., Nakamura, I., Ikebe, T., Akiyama, S., Takahashi, N. and Suda, T. 1998. Activation of NF-kappa B is involved in the survival of osteoclasts promoted by interleukin-1. J. Biol. Chem. 273:8799.
55. Lee, S. K., Gardner, A. E., Kalinowski, J. F., Jastrzebski, S. L. and Lorenzo, J. A. 2006. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone 38:678.
56. Kim, J. H., Jin, H. M., Kim, K. et al. 2009. The mechanism of osteoclast differentiation induced by IL-1. J. Immunol. 183:1862.
57. Lee, S. K., Kalinowski, J., Jastrzebski, S. and Lorenzo, J. A. 2002. 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleenosteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. J. Immunol. 169:2374.
58. Horwood, N. J., Elliott, J., Martin, T. J. and Gillespie, M. T. 1998. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139:4743.
59. Udagawa, N., Takahashi, N., Yasuda, H. et al. 2000. Osteoprotegerin (OPG) produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478.